이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Understanding the Burden and Post-Discharge Management of Severe Malarial Anaemia and Severe Malaria Among Tanzanian Children: An Epidemiological and Qualitative Study (PODSMA-TZ)

2026년 11월 19일 업데이트: Ifakara Health Institute

This study will examine what happens to children aged 3 months to 5 years after hospital discharge following severe malaria or severe malarial anaemia (a very low blood level caused by malaria). It will take place at Newala District Hospital in Tanzania.

Researchers will review hospital records from the previous two years. They will also follow 250 children for 12 weeks after hospital discharge.

The study will examine:

  1. Whether children die or return to hospital after discharge.
  2. Whether children experience malaria again after discharge.
  3. How children's blood levels recover after severe illness.
  4. The healthcare services families use and the costs they face.

Researchers will also interview caregivers, community health workers and healthcare providers. These interviews will explore experiences, challenges and support available to children after hospital discharge.

The findings will help improve understanding of children's recovery after severe malaria. They may also inform future approaches to follow-up care and support for affected children.

This is an observational study. Researchers will not give participants any study medicine or additional treatment.

연구 개요

상태

아직 모집하지 않음

정황

상세 설명

PODSMA-TZ is a non-interventional, observational mixed-methods study conducted at Newala District Hospital, Mtwara Region, Tanzania. The study combines retrospective review of routine hospital records, prospective follow-up of children discharged after severe malaria or severe malarial anaemia (SMA), and qualitative research.

The retrospective component will review routinely collected hospital records from the preceding two years. Basic admission information will be abstracted for all children aged 3 months to 5 years to establish the denominator of paediatric admissions. More detailed demographic, clinical, laboratory, treatment and outcome information will be collected for children diagnosed with severe malaria or SMA according to World Health Organization criteria.

The prospective component will involve observational follow-up of eligible children after hospital discharge. Information will be collected on their health and recovery, healthcare utilisation, care-seeking practices and medication adherence. Healthcare-related costs and household expenditures associated with care will also be documented during follow-up.

The qualitative component will explore experiences and challenges associated with post-discharge care. Approximately 30 caregivers will participate in in-depth interviews. An estimated 20-25 healthcare providers will participate in key-informant interviews. Additionally, 4-6 focus group discussions will be conducted with community health workers, with 6-8 participants in each group.

Qualitative discussions will explore experiences of caring for children after severe malaria, barriers and facilitators to accessing follow-up care, malaria prevention practices, and awareness and perceptions of potential future post-discharge malaria chemoprevention (PDMC) and monoclonal antibody interventions. These discussions will also explore acceptability and readiness for possible future implementation of these approaches.

Interviews and focus group discussions will be audio-recorded with participants' consent, transcribed in Kiswahili and translated into English where required.

The study does not involve randomisation, allocation to intervention groups or administration of study treatments. Clinical care will continue according to routine healthcare practice.

연구 유형

관찰

등록 (추정된)

250

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Mtwara
      • Newala, Mtwara, 탄자니아, 63422
        • Newala District Hospital
        • 연락하다:
        • 수석 연구원:
          • Kamaka R Kassimu, PhD
        • 부수사관:
          • Scolastica L Lusenge, MD
        • 부수사관:
          • Tunu H Ndanzi, Msc.
        • 부수사관:
          • Abdallah S Lusasi, MPH
        • 부수사관:
          • Hassan T Berenge, MA (PME)

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

3개월 (어린이)

건강한 자원 봉사자를 받아들입니다

해당 없음

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Children aged 3 months to 5 years admitted with severe malaria or SMA at Newala District Hospital and followed after discharge; paediatric hospital admission records for the two-year retrospective review; and caregivers, healthcare providers and community health workers involved in post-discharge care in Newala District.

설명

Eligibility - Retrospective

Inclusion Criteria:

  • All paediatric admissions aged 3 months to 5 years during the two-year review period contribute basic admission information; detailed clinical abstraction for records of children diagnosed with severe malaria or SMA according to WHO criteria.

Exclusion Criteria:

  • Records outside age range; insufficient information to determine eligibility, diagnosis or outcome; inadequate documentation to confirm severe malaria or SMA. Eligibility - Prospective Cohort

Inclusion criteria:

- Child aged 3 months to 5 years; admitted with severe malaria or SMA; clinically stable for discharge; parent/legal guardian provides written informed consent.

Exclusion criteria:

  • Declined/no consent; prior enrolment in prospective cohort; known chronic conditions requiring long-term specialised care (e.g., malignancy or severe congenital disease requiring tertiary management). Common co-existing conditions including severe acute malnutrition, HIV, sickle cell disease, pneumonia and sepsis are not exclusion criteria. Eligibility - Qualitative
  • Caregivers of enrolled children, healthcare providers and community health workers. Participation is voluntary; individuals who decline or are unable to participate in Kiswahili without translation support are excluded.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: OTHER
  • 시간 관점: OTHER

코호트 및 개입

그룹/코호트
Children discharged after severe malaria or severe malarial anaemia (prospective cohort).

Approximately 250 children aged 3 months to 5 years admitted with severe malaria or SMA, clinically stable for discharge and enrolled at discharge following written guardian consent. Follow-up at Weeks 1, 4, 8 and 12. No intervention or assigned exposure.

Retrospective paediatric hospital records

Routinely collected records of all children aged 3 months to 5 years admitted during the preceding two-year review period provide denominator data. Detailed abstraction is undertaken for records of children diagnosed with severe malaria or SMA according to WHO criteria. This is a records-based component, not an intervention group.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
All-cause post-discharge mortality.
기간: Day 0 through Day 84 after discharge/enrolment.

Death from any cause during the 12-week post-discharge period, reported as the proportion of enrolled children who die. Day 0 is discharge/enrolment.

Day 0 through Day 84 after discharge/enrolment.
Hospital readmission
기간: Day 0 through Day 84

One or more overnight rehospitalisations for any cause during the 12-week follow-up. Summarise the proportion with any readmission and total number of readmissions

Day 0 through Day 84
Recurrent clinical malaria
기간: Day 0 through Day 84

Time to first recurrent malaria episode, defined as a positive malaria RDT or microscopy result accompanied by fever or history of fever

Day 0 through Day 84
Anaemia recovery among children with SMA at baseline.
기간: Week 12 assessment; permitted visit window up to 7 days after Day 84 (Days 85-91).

Achievement of haemoglobin concentration ≥10 g/dL at the Week 12 assessment among participants with SMA at baseline.

Week 12 assessment; permitted visit window up to 7 days after Day 84 (Days 85-91).
Haemoglobin trajectory
기간: Baseline/discharge through Weeks 1, 4, 8 and 12; Week 12 may occur within the permitted +7-day window.

Change in haemoglobin concentration across baseline and follow-up assessments. Baseline haemoglobin is the admission measurement if available; otherwise, the discharge/enrolment measurement is used.

Baseline/discharge through Weeks 1, 4, 8 and 12; Week 12 may occur within the permitted +7-day window.

2차 결과 측정

결과 측정
측정값 설명
기간
Epidemiological and clinical patterns of severe malaria and severe malarial anaemia.
기간: Retrospective two-year record review; prospective admission through discharge for clinical/in-hospital outcomes, with post-discharge healthcare utilisation and costs assessed through Day 84 (12 weeks).

Distribution of admissions by age, sex and geographical origin; clinical/laboratory characteristics; parasite density where available; comorbidities; monthly and seasonal trends; and in-hospital outcomes. Healthcare utilisation and direct post-discharge healthcare costs will also be summarised.

Retrospective two-year record review; prospective admission through discharge for clinical/in-hospital outcomes, with post-discharge healthcare utilisation and costs assessed through Day 84 (12 weeks).

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2027년 3월 31일

기본 완료 (추정된)

2028년 6월 30일

연구 완료 (추정된)

2028년 6월 30일

연구 등록 날짜

최초 제출

2026년 11월 12일

QC 기준을 충족하는 최초 제출

2026년 11월 19일

처음 게시됨 (실제)

2026년 11월 20일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 20일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 19일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 23540
  • 337563 (기타 보조금/기금 번호: GSK African Open Lab)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

IPD 계획 설명

To be confirmed by sponsor and PI. Protocol allows de-identified data sharing subject to institutional and applicable data-protection requirements but does not specify a formal public IPD-sharing commitment.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .